drugset / Trial / NCT00751166

A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)

NCT00751166

Phase 4 Terminated 149 enrolled Organon and Co
RandomizedParallel-groupTriple-blindTreatment

Summary

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.

Timeline

Start
2004-03-01
Primary completion
2005-05-01
Completion
2005-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetirizine Other / unclassified 10 mg Oral
Subject Desloratadine Small molecule 5 mg Oral

Indications